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Mutations in the postsynaptic scaffolding gene SHANK2 have recently been identiﬁed in individuals with
autism spectrum disorder (ASD) and intellectual disability. However, the cellular and physiological conse-
quences of these mutations in neurons remain unknown. We have analyzed the functional impact caused
by two inherited and one de novo SHANK2 mutations from ASD individuals (L1008_P1009dup, T1127M,
R462X). Although all three variants affect spine volume and have smaller SHANK2 cluster sizes, T1127M add-
itionally fails to rescue spine volume in Shank2 knock-down neurons. R462X is not able to rescue spine
volume and dendritic branching and lacks postsynaptic clustering, indicating the most severe dysfunction.
To demonstrate that R462X when expressed in mouse can be linked to physiological effects, we analyzed
synaptic transmission and behavior. Principal neurons of mice expressing rAAV-transduced SHANK2-
R462X present a speciﬁc, long-lasting reduction in miniature postsynaptic AMPA receptor currents. This
dominant negative effect translates into dose-dependent altered cognitive behavior of SHANK2-R462X-
expressing mice, with an impact on the penetrance of ASD.
INTRODUCTION
Autism spectrum disorder (ASD) comprises a group of genet-
ically heterogeneous neurodevelopmental disorders with an
estimated prevalence of 1% in the childhood population.
ASD is characterized by an impairment of social interaction
and communication, accompanied by a pattern of repetitive
and restrictive behavior, typically diagnosed in the ﬁrst 3
years of life (1). It can either occur as a single entity, in com-
bination with intellectual disability (ID) or associated with
genetic syndromes such as Fragile X and Rett syndrome (2).
Rare variants seem to play a much greater role in autism
risk than common variants (3).
Autism manifests before the age of 3 years and persists
throughout life. The ﬁrst few years of life are also the time
during which synaptic contacts between neurons are established,
strengthened and remodeled. The formation and maturation of
synapses is a tightly regulated process ensuring correct connec-
tions between neurons and a deﬁned balance between excitatory
and inhibitory input. A remarkable number of genes that are
crucial for synaptogenesis and synapse function have been
reported in recent years to cause various psychiatric and
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pothesis that synaptic plasticity in the brain is essential for our
ability to learn, memorize and socially communicate.
In previous studies, mutations and copy number variations
in the scaffolding gene SHANK2 have been reported in indivi-
duals with ASD and ID (6,7). SHANK2 is a member of a
family of scaffold proteins (comprising SHANK1, 2 and 3)
that localize to the postsynaptic site of excitatory synapses
in the central nervous system (8). SHANKs are among the
most abundant scaffolding proteins which co-ordinate the
organization of the postsynaptic density (PSD). They interact
with each other and other core scaffolding proteins of the
PSD (e.g. PSD95, Homer and GKAP) and form a mesh-like
structure for the assembly of various postsynaptic proteins
and signaling molecules (9). SHANK proteins also link
iono- and metabotropic glutamate receptor complexes together
and to the cytoskeleton. The largest neuronal isoform of
SHANK2 (6,10) is speciﬁcally expressed in the brain and con-
tains an SH3 domain followed by a PDZ domain, a long
proline-rich region and a C-terminal SAM domain (Fig. 1A).
To unravel the functional activity of SHANK2 variants, we
have carried out a comprehensive functional analysis of
variants with low (L1008_P1009dup, T1127M) and high
(R462X) penetrance (6). The analysis ranged from morpho-
logical studies in cultured hippocampal neurons to virus-
based gene expression in mice for electrophysiological and
behavioral analyses of the SHANK2 variants ex vivo and
in vivo, respectively. We here report that previously identiﬁed
SHANK2 mutations have distinct consequences on morpho-
logical (L1008_P1009dup, T1127M, R462X) and electro-
physiological (R462X) properties of synapses that are
paralleled by behavioral abnormalities in the intact animal.
RESULTS
SHANK2 variants are misplaced and functionally altered
To uncover the functional activity of rare SHANK2 variants,
we investigated the effects of an R462X stop mutation, an
L1008_P1009 duplication and a T1127M missense variant
that were all detected in patients with ASD (6). The R462X
mutation occurred de novo while the duplication and the mis-
sense variants were both inherited from apparently healthy
mothers. We selected these two inherited variants because
they localize at highly conserved positions in SHANK2; the
T1127M mutation resides in the highly conserved Dynamin-2-
binding motif and the L1008_P1009dup mutation in direct
vicinity to the Homer-binding motif, suggesting that this
may alter SHANK2 protein function. Mothers with the
T1127M and L1008_P1009dup variants had a family history
of learning difﬁculties or developmental delay.
To study the effects of the SHANK2 variants on the morph-
ology of primary neurons, we overexpressed all three variants
and the SHANK2 wild-type (WT) in primary hippocampal
neurons as mCherry fusion proteins (Fig. 1A). Western ana-
lysis in HEK293 cells indicated an identical size of
SHANK2 WT and variant L1008_P1009dup and T1127M
using a SHANK2 primary antibody, whereas the stop mutation
(R462X) resulted in the truncation of the protein (Fig. 1B).
In primary hippocampal neurons, SHANK2-WT exclusively
accumulated in dendritic spines and localized postsynaptically
to synapsin 1 (Fig. 1C and D). In contrast, the truncated
SHANK2 (R462X) was evenly distributed throughout the
dendrites and accumulated in the cell soma. The R462X
variant did not co-localize with synapsin 1, suggesting that it is
not efﬁciently targeted to functional synapses (Fig. 1C and D).
The T1127M and the L1008_P1009dup variant still localized
to synapses (Fig. 1C and E) but displayed smaller protein accu-
mulations in the spines, compared with WT (Fig. 1F).
To analyze the effect of the variants on dendritic spine
volume, we transfected primary hippocampal neurons with
GFP and mCherry-SHANK2 fusion constructs (Supplemen-
tary Material, Fig. S1A). High-resolution z-stack images of
GFP-positive neurons were taken with a confocal laser scan-
ning microscope to measure the ﬂuorescence intensity of
GFP within the three-dimensional projections, which in turn
allowed us to calculate the relative spine volumes. Overex-
pressing SHANK2-WT, we detected a signiﬁcant increase in
dendritic spine volume, similar to previously described ﬁnd-
ings (11) (Supplementary Material, Fig. S1A and B). For the
SHANK2 mutants, we found in three independent
experiments, analyzing more than 3600 spines from 18
neurons for each condition, that the SHANK2-R462X stop
mutant entirely lacks the potential to increase spine volume
(Supplementary Material, Fig. S1A and B). Similarly, also
the SHANK2-T1127M and the L1008_P1009dup variants
had no signiﬁcant effect on the increase in spine volume (Sup-
plementary Material, Fig. S1C). The lack of SHANK2 protein
function of the stop mutant (R462X) might be caused by its
misplaced localization due to the loss of the C-terminal
SAM domain and the adjacent binding motifs for the inter-
action with Homer, Cortactin and Dynamin 2. In contrast,
SHANK2-T1127M and the L1008_P1009dup might affect
SHANK2 protein function rather than localization because
they both still localize to dendritic spines but display signiﬁ-
cantly smaller clusters that might result in an altered PSD
Figure 1. Overexpression of SHANK2 mutants R462X, L1008_P1009dup and T1127M in primary hippocampal neurons. (A) SHANK2 WT and mutant con-
structs fused N-terminal with mCherry. SH3 (Src homology 3), PDZ (postsynaptic density 95/discs large/zona occludens-1), proline-rich region and SAM (sterile
alpha motif) indicate the functional domains of SHANK2. Binding motifs for Homer (H), Dynamin 2 (D) and Cortactin (C) are indicated. (B) Western blot
analysis displaying the sizes of the different SHANK2 constructs. Endogenous SHANK2 is not present in HEK293 cells. (C) Representative hippocampal
neurons transfected with GFP in addition to overexpression with mCherry-SHANK2 WT, mCherry-SHANK2-R462X, mCherry-SHANK2-L1008_P1009dup
or the mCherry-SHANK2-T1127M mutant. Scale bars: 10 mm (main panels); 2.5 mm (insets). (D) SHANK2 WT, the T1127M and the L1008_P1009dup
mutant are located at functional synapses opposed to the presynaptic marker synapsin 1 (indicated by arrows). In contrast, the truncated SHANK2 mutant
R462X did not cluster at functional synapses. Scale bars: 2 mm. (E) Quantitative analysis of the clustering behavior of the SHANK2 mutants shown in (A).
The average pixel intensity in dendrites versus spine heads was measured to determine the SCR for WT and mutants. SCR ¼ 1 indicates no clustering or
even distribution, SCR ¼ 0 indicates complete clustering. (F) Cumulative distribution of SHANK2 WT, L1008_P1009dup and T1127M cluster sizes. The
R462X mutant did not cluster at all. SHANK2 WT clusters are larger compared with the two mutants. Kolmogorov–Smirnov test: WT/L1008_P1009dup
P , 10
29 D ¼ 0.121; WT/T1127M P , 10
27 D ¼ 0.077 (n ¼ 3, 18 neurons for each condition).
Human Molecular Genetics, 2012, Vol. 21, No. 2 345346 Human Molecular Genetics, 2012, Vol. 21, No. 2Figure 2. shRNA-mediated knock-down of endogenous Shank2 reduces spine volume and increases dendritic arborization. (A) Representative ﬁgures of rat hip-
pocampal neurons co-transfected with GFP and control shRNA (co-shRNA), shRNA#1 or shRNA#2, directed against Shank2. Knock-down of Shank2 results in
many thin ﬁlopodia-like dendritic spines, most of them do not contain Shank2, whereas most spines under control conditions are mushroom-shaped and express
Shank2 in their spine heads (indicated by arrows). Scale bar, 4 mm. (B) Representative neurons demonstrating that loss of Shank2 increases the complexity of
the dendritic arbor. Scale bar, 23 mm. (C) Co-staining of primary hippocampal neurons with the presynaptic marker synapsin 1 (blue) and the postsynaptic
marker PSD 95 (red). Shank2 knock-down neurons show a decrease in synaptic density. Scale bar, 2.5 mm. (D) Quantiﬁcation of the Shank2 knock-down in
primary hippocampal neurons. Bars represent the overall density of Shank2 puncta within a deﬁned dendritic area. Both shRNAs signiﬁcantly reduce the
Shank2 puncta density (shRNA#1 P ¼ 2.2 × 10
27; shRNA#2 P ¼ 8.9 × 10
29). (E) Quantitative analysis of the relative dendritic spine volume. The shRNAs sig-
niﬁcantly reduce spine volume (shRNA#1 P ¼ 2 × 10
218; shRNA#2 P ¼ 2 × 10
219)( n ¼ 3, 4200 spines from 21 neurons for each condition). (F) Shank2 knock-
down reduces the synaptic density in primary hippocampal neurons. Synapse number was determined by counting the number of dendritic spines positive for
PSD-95/synapsin that co-cluster along the dendritic area (shRNA#1 P ¼ 4.3 × 10
212; shRNA#2 P ¼ 4.4 × 10
211). (G) Knock-down of Shank2 had no effect
on dendritic spine density (n ¼ 3 experiments, 18 neurons for each condition). (H and I) Quantiﬁcation of the dendritic complexity by Sholl analysis. (H)
Shank2 knock-down increases the total number of intersections (shRNA#1 P ¼ 2.1 × 10
25; shRNA#2 P ¼ 0.002). (I) Loss of Shank2 increases dendritic material
proximal to the soma relative to control conditions. P-values are still signiﬁcant across the different groups after correction for multiple testing by the Bonferroni
methodP ≤ 0.005(D–I).Allvaluesareshownasmean+SD. ∗∗P ≤ 0.01, ∗∗∗P ≤ 0.001;shRNAvaluesarealwayscomparedwiththeGFPcontrol.ControlshRNA
has no signiﬁcant effect on the parameters. ANOVA P , 0.001, P-values of post hoc Scheffe ´ tests are given (D, F, H and I) (n ¼ 3, 30 neurons for each condition).
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variants are impaired in function, with the most striking defect
seen for the displaced R462X mutant.
SHANK2 variants fail to rescue Shank2 knock-down in
primary hippocampal neurons
To investigate the effect of reduced SHANK2 protein levels as
predicted for individuals with ASD with a de novo
microdeletion of the SHANK2 gene (6), we performed RNAi-
mediated knock-down of Shank2 in primary hippocampal
neurons. We used two shRNAs (#1, #2), which target different
regions of Shank2 efﬁciently. HEK293 cells were
co-transfected with either of the two shRNAs and Shank2
from Rattus norvegicus or human SHANK2. Rat Shank2 ex-
pression was speciﬁcally reduced but the expression of rat
Shank1, rat Shank3 and human SHANK2 was not altered, in-
dicating speciﬁcity (Supplementary Material, Fig. S2A). In
shRNA#2-transfected cortical neurons, the endogenous
Shank2 protein level was almost 50% reduced as indicated
by western blot analysis (Supplementary Material, Fig.
S2B). Similarly, in cultured hippocampal neurons, endogenous
Shank2 protein levels were reduced by approximately half
with both shRNAs, as measured by counting the number of
Shank2 puncta along the dendrites (Fig. 2A and D). The
reduced Shank2 expression signiﬁcantly decreased spine
volume (Fig. 2A and E), but had no effect on spine density
(Fig. 2G). Reduced spine volume was accompanied by a sig-
niﬁcant decrease in the number of functional synapses along
the dendrites indicated by co-localization of the postsynaptic
marker PSD95 and the presynaptic marker Synapsin 1
(Fig. 2C and F). Under control conditions (control-shRNA),
the majority of dendritic spines show a mature mushroom-
shaped morphology, whereas the knock-down of Shank2 pre-
sented thin ﬁlopodia-like immature spines in the majority of
cells (Fig. 2A). Hippocampal neurons with reduced Shank2
expression furthermore showed an increase of dendritic com-
plexity (Fig. 2B). We performed Sholl analysis by counting
the intersections of dendrites with overlay of concentric
rings at 25 mm intervals centered on the cell soma, to describe
the amount and distribution of dendrites. The total number of
dendritic branches was signiﬁcantly increased in Shank2
knock-down neurons compared with the GFP control condi-
tions (Fig. 2H), with an accelerated growth of dendrites
close to the cell soma (Fig. 2I).
We next asked whether SHANK2 WT and mutants are able
to rescue the Shank2 knock-down phenotype in primary hip-
pocampal neurons by co-transfection of shRNA#2 (directed
against rShank2) with either the human SHANK2-WT or
one of the three variants, respectively. Human SHANK2-WT
and the duplication variant (L1008_P1009dup) were able to
rescue the knock-down-mediated phenotype, normalizing
both the dendritic spine volume and dendritic arbor develop-
ment (Fig. 3A and C). In contrast, the R462X and T1127M
variant could not rescue the reduced spine volume (Fig. 3A).
As shown in Figure 3B, expression of SHANK2-WT
reduces the total number of intersections below GFP control
levels. In contrast to these ﬁndings, overexpression of
SHANK2 has no effect on dendritic arbor development. In
the Sholl analysis, the distribution of dendritic material
throughout the neuron and the total number of intersections
was not altered (Supplementary Material, Fig. S3). Comparing
the degree of rescue obtained with either human
SHANK2-WT or the three variants, we can demonstrate that
only the R462X variant fails to rescue the excessive branching
to a normal level, an effect that fades out 75 mm away from
the cell body (Fig. 3B and C). In this respect, the missense
and duplication variants behave like WT normalizing the
number of intersections. The R462X mutant has the most
Figure 3. Rescue of Shank2 knock-down. (A) Human SHANK2 WT protein
normalizes spine volume in Shank2 knock-down neurons, whereas the
SHANK2 R462X and the T1127M mutants have lost this ability (shRNA#2
P ¼ 4.4 × 10
27; SHANK2-WT P ¼ 0.787; R462X mutant P ¼ 4.7 × 10
211,
T1127M mutant P ¼ 1.4 × 10
25; compared against GFP; n ¼ 3, 21 neurons
for each condition). The L1008_P1009dup mutant rescues the spine volume
to some extent but is not as efﬁcient as WT protein (GFP/shRNA#2
P ¼ 4.4 × 10
27, GFP/L1008_P1009dup P ¼ 0.066). (B and C) Human WT
SHANK2, the T1127M and the duplication variants normalize dendritic arbor-
ization in SHANK2 knock-down neurons, as determined by Scholl analysis. In
contrast, the R462X mutation is not able to rescue the increased dendritic
branching. (B) Analysis of the total amount of intersections. Pair-wise
P-values: GFP/shRNA P ¼ 0.001, GFP/SHANK2-WT P ¼ 0.024,
SHANK2-WT/R462X P ¼ 2.3 × 10
26; SHANK2-WT/T1127M and
SHANK2-WT/L1008_P1009dup P-values are not signiﬁcant. Only the
R462X mutant fails to rescue the excessive dendritic branching, whereas the
two missense variants behave like WT. (C) Distribution of intersections
across the neuron. The R462X mutant is not able to rescue the increase in
branching near the cell body within a distance of 50 mm( n ¼ 3, 30 neurons
for each condition). Values for T1127M, L1008_P1009dup and Shank2-WT
are similar to the GFP control. ∗P ≤ 0.05, ∗∗∗P ≤ 0.001, ANOVA P ,
0.001; P-values of post hoc Scheffe ´ test are given.
348 Human Molecular Genetics, 2012, Vol. 21, No. 2Figure 4. Expression of SHANK2-R462X in the hippocampal CA1 cells is correlated with reduced mEPSCs in mice and causes morphological changes in vivo.
(A) Top: Diagram of rAAV constructs containing SHANK2-WT and SHANK2-R462X. Bottom (left): Fluorescence confocal images of the hippocampal area
CA1 in brain sections of adult mice injected at P42 with rAAV-Venus2A-SHANK2-WT and rAAV-Venus-SHANK2-R462X. Bottom (center): Cumulative amp-
litude distributions for mEPSCs and mIPSCs recorded at P69+1 from CA1 pyramidal cells in brain slices from SHANK2-WT (green) and SHANK2-R462X
(blue) infected mice. SHANK2-R462X mice display intact inhibitory signaling, but  26% reduced AMPAR-mediated transmission. This is reﬂected as a left-
ward shift of the distribution of mEPSC amplitudes. Group-average mEPSC and mIPSC traces acquired from the same cells (see Materials and Methods). Decay-
time constants for the miniature currents are all similar (mIPSC, control: 14.8+0.3, n ¼ 16; SHANK2-WT: 17.3+1.1, n ¼ 18; SHANK2-R462X: 16.8+1.3,
n ¼ 21; F(2,51) ¼ 1.6119, P ¼ 0.1339). Right: Summary graphs for averaged mEPSC and mIPSC amplitudes and frequencies. No differences in mEPSC fre-
quency were detected. This indicates that the mutation affects postsynaptic excitatory transmission. The anti-GFP immunostaining reﬂects a volume labeling
of soluble Venus released in Venus-2A-SHANK2-WT-expressing cells, whereas the Venus-SHANK2-R462X is expressed as Venus fusion protein with an
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cation shows no functional loss in the rescue experiment. The
loss-of-function effect of the T1127M variant is restricted to
the dendritic spines. Given the disparate effects of different
Shank2 mutants on dendrite and spine morphology, this sug-
gests that either Shank2 is involved in the regulation of two
separate pathways controlling dendrite or spine morphology,
respectively, or that spine growth is more sensitive to a reduc-
tion in Shank2 activity compared with dendrite arborization.
Miniature EPSCs are speciﬁcally reduced by
SHANK2-R462X overexpression
We next studied the physiological effects of R462X in vivo by
rAAV-mediated gene delivery of Venus-tagged R462X into
the hippocampus of adult mice. Three weeks after rAAV infec-
tions, at postnatal day P69+1, the ex vivo recordings of iso-
lated AMPAR-mediated miniature excitatory postsynaptic
currents (mEPSCs, see Materials and Methods) of Venus-
positive CA1 pyramidal cells showed that the average
mEPSC amplitude was signiﬁcantly reduced by  26% in
SHANK2-R462X-infected neurons compared with
SHANK2-WT overexpressing and WT neurons (Fig. 4A, Sup-
plementary Material, Table S1). Since in age-matched mice
the mEPSC amplitude between control and SHANK2-WT
expressing cells is not signiﬁcantly different, we conclude that
R462X has a direct pathophysiological effect by reducing the
mEPSC amplitude. The mEPSC frequency was similar for all
groups, indicating that the SHANK2-R462X expression
mainly affects AMPA-receptor-mediated postsynaptic excita-
tory transmission. No changes in mEPSC decay times
between groups were detected. Analysis of inhibitory transmis-
sion (12) into the same cells (see Materials and Methods)
showed that the amplitude and frequency distributions of spon-
taneous inhibitory currents (mIPSCs) were similar across ex-
perimental groups. Thus, neither the inhibitory drive in
principal neurons nor the root mean square (RMS) current
noise levels, input resistance and other neuronal control proper-
ties were affected by the overexpression of SHANK2-R462X
(Fig. 4A, Supplementary Material, Table S1).
Next, we investigated whether viral SHANK2-R462X trans-
duction by injection of rAAV into the brains of newborn mice
(13) was long lasting. We injected Venus-tagged
SHANK2-WT and Venus-tagged SHANK2-R462X at P0
and recorded mEPSCs and mIPSCs 3 months later in brain
slices (Fig. 4B). Venus-positive pyramidal cells located
either in the hippocampal CA1 region or in layer 2/3 of the
entorhinal cortex (EC) were selected for recordings
(Fig. 4B). The average mIPSC amplitude and frequency
obtained from Venus-positive CA1 and from layer 2/3 pyram-
idal cells remained similar between rAAV SHANK2-WT and
rAAV SHANK2-R462X mutant infected mice, as in the CA1
cells of adult injected mice (Fig. 4B). In contrast, however,
the average mEPSC amplitudes from SHANK2-R462X-
expressing CA1 and layer 2/3 pyramidal cells (Fig. 4B)
were decreased by  33 and  17%, respectively, compared
with corresponding SHANK2-WT-expressing cells. The
mEPSC frequency and other control neuronal parameters
were similar across groups (Supplementary Material,
Table S1), demonstrating that the persistent expression of
SHANK2-R462X leads to a postsynaptically localized reduc-
tion of AMPA-receptor-mediated currents.
However, the high-resolution analysis of the AMPA recep-
tor distribution at CA1 synapses in the stratum radiatum
revealed an increased size and number of AMPA receptor
clusters in adult SHANK2-R462X-expressing mice compared
with GFP-expressing controls (Fig. 4C and D). The Golgi stain
showed densely packed ﬁlopodia structures instead of mature
spines at CA1 dendrites of SHANK2-R462X-expressing mice
(Fig. 4E), which might indicate that AMPA receptor clusters
in the neuropil of SHANK2-R462X mice are not localized at
active synapses. This hypothesis is supported by the reduced
surface expression of AMPA receptors in primary hippocam-
pal neurons overexpressing SHANK2-R462X. By immunos-
taining, we observed a subtle but signiﬁcant decrease in
AMPA receptor cluster sizes at spine heads of neurons overex-
pressing SHANK2-R462X in comparison with GFP/mCherry
control conditions (Supplementary Material, Fig. S4). A
reduced amount of AMPA receptors at the spines of neurons
is consistent with the decrease in mEPSC currents observed
in mice.
enriched nuclear localization as also noticed in transfected primary neurons. (B) Top: Confocal ﬂuorescence images of Venus-positive pyramidal cells in the
hippocampal area CA1 and cortical layer 2/3 (right) injected at P0 with rAAV-Venus2A-SHANK2-WT and rAAV-Venus-SHANK2-R462X. Scale bar,
10 mm. Bottom (left): Cumulative amplitude distributions for mEPSCs and mIPSCs recorded from CA1 pyramidal cells from Shank2-WT (green) and
SHANK2-R462X (blue) P0-infected mice at P100+2 (average of 300 mPSCs per cell per mouse). P0-injected mice produced consistent results:
SHANK2-R462X displays an  33% reduction in AMPAR-mediated transmission without differences in mPSC decay-kinetics [mEPSC (in ms),
SHANK2-WT: 4.4+0.6, n ¼ 20; SHANK2-R462X: 3.4+0.3, n ¼ 22; F(1,39) ¼ 1.4303, P ¼ 0.2387; mIPSC decay-time (in ms), SHANK2-WT: 16.1+0.9,
n ¼ 20; SHANK2-R462X: 14.0+2.0, n ¼ 22; F(1,39) ¼ 3.0959, P ¼ 0.0861] or in mPSC frequencies [mIPSC frequencies (in Hz), SHANK2-WT: 8.6+0.5,
n ¼ 20; SHANK2-R462X: 7.7+0.5, n ¼ 22; F(1,39) ¼ 1.8317, P ¼ 0.1835]. Bottom (right): Cumulative amplitude distributions for mEPSCs and mIPSCs
recorded from infected pyramidal neurons in EC layer 2/3 at P69 + 1. SHANK2-R462X mice present an  17% reduction of AMPAR but no change in
GABAA-R-mediated transmission [mean mIPSC amplitude (in pA), SHANK2-WT: 23.6+1.2, n ¼ 21; SHANK2-R462X: 23.8+1.3, n ¼ 24; one-way
ANOVA, F(1,41) ¼ 0.0127, P ¼ 0.9106]. mPSC frequency [mIPSC frequency (in Hz), SHANK2-WT: 5.9+0.6, n ¼ 21; SHANK2-R462X: 5.9+0.4, n ¼
24; F(1,41) ¼ 0.0090, P ¼ 0.9246] and mPSC decay kinetics [mEPSC-decay time, SHANK2-WT: 6.1+0.3, n ¼ 20; SHANK2-R462X: 5.7+0.6, n ¼ 21;
F(1,41) ¼ 0.9733, P ¼ 0.3294; mIPSC-decay time (in ms), SHANK2-WT: 13.3+0.7, n ¼ 21; SHANK2-R462X: 11.2+0.4, n ¼ 24; F(1,41) ¼ 3.9014, P ¼
0.5119] were similar for both groups. (C) GluA1 cluster staining of SHANK2-R462X mice compared with GFP control overexpressing mice. Left panel
shows the overview of GluA1 staining in the CA1 region of a P0 infected hippocampus. Scale bar, 10 mm. Confocal stacks were taken from
rAAV-Syn-Venus-SHANK2-R462X and rAAV-Syn-GFP infected stratum radiatum regions of the hippocampus. Center and right panels: Overlaying red
dots show the GluA1 stained clusters as they were counted in ImageJ. Scale bar, center, 5 mm; right, 2.5 mm. (D) Statistical analysis shows signiﬁcant differences
of GluA1 cluster number and cluster size between SHANK2-R462X and GFP overexpressing animals (P , 0.0001). (E) Golgi staining of SHANK2-R462X P0
infected hippocampal CA1 neurons and PBS P0 treated hippocampal CA1 neurons. The SHANK2-R462X mice showed densely packed ﬁlopodia structures
instead of mature spines. Scale bar, 5 mm. ∗P ≤ 0.05, ∗∗∗P ≤ 0.001.
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SHANK2-R462X for 2–3 weeks in the brain of adult mice
has a dominant negative effect. SHANK2-R462X expression
is sufﬁcient to reduce the amplitude, but not the kinetics of
excitatory AMPAR-mediated transmission. It does not affect
the inhibitory drive converging into SHANK2-R462X-expres-
sing cells, and it leads to changes in spine structures and
AMPA receptor distribution.
Postnatally expressed SHANK2-R462X mutant alters
mouse cognitive behavior
The strong and persistent expression of SHANK2-R462X in
the brain of P0 injected mice might permit a ﬁrst behavioral
analysis of mice overexpressing SHANK2-R462X in the neo-
cortex. We used well-established tests for locomotor activity,
novel object exploration and executive functions that have
been previously shown to be sensitive to altered AMPA recep-
tor signaling (14,15).
Thepostmortemanalysisofthemousebrainsshowedthatthe
GFPsignalinrAAV-injectedmice(P0)was5-foldstrongerthan
thesignalforVenusofrAAV-SHANK2-R462Xinjectedmice7
months after injection (Fig. 5A and C). In both mouse cohorts,
the GFP as well as the Venus-SHANK2-R462X expression
was prominent in the cortex and hippocampus (Fig. 5B and
D). By quantitative immunoblotting, the rAAV-injected mice
could be divided into high (H) and low (L) expressing mice
(Fig. 5D), whereas the endogenous AMPA receptor subunit
levels for GluA1 and GluA2 and the amount of phosphorylated
GluA1isoformsGluA1-S831andGluA1-S845wereunchanged
inbothgroups(Fig.5E).Sincetheviraltransducedgenesarenot
expressed ubiquitously, alteration in AMPA receptor expres-
sionorphosphorylationcannotbeexcludedatthecellular level.
For a closer behavioral analysis, we divided the group of
rAAV-SHANK2-R462X-expressing mice in high and low
expressing animals (Fig. 5)b yapost hoc median split. At
the age of 3–4 months, all mice showed comparable body
weight and regular locomotor behavior in the rotarod and in
the open ﬁeld test (Fig. 6A and data not shown). In the open-
ﬁeld test, however, when a novel object was introduced into
the center of the open arena, only AAV-GFP control injected
mice showed the expected high exploration rate of the novel
object (P , 0.01), whereas both SHANK2-R462X-expressing
groups did not exhibit signiﬁcant increase in object explor-
ation (Fig. 6B). Moreover, we subjected the mice to an
escape task testing executive functions [the so-called puzzle
box test (15)] in which the animals have to escape from a lit
compartment into a dark compartment, with increasing difﬁ-
culty of escape strategies from trial 1 to 11. In this test, high-
level SHANK2-R462X-expressing mice showed a signiﬁcant
impairment (P , 0.01) compared with low level and
GFP-expressing mice, respectively, in the more difﬁcult
trials requiring elaborated escape strategies (Fig. 6D).
This phenotype was not confounded by alterations in anxiety
behavior, since all groups showed similar emotional behavior
in a standardized light–dark box test with simple escape pos-
sibilities (Fig. 6C). In summary, our data demonstrate that the
postnatal expression of the SHANK2-R462X in mice can lead
to impaired cognitive functions.
DISCUSSION
The neuropathological signiﬁcance of rare variants in ASD has
been difﬁcult to assess in the past. We have now
Figure 5. StrongexpressionofSHANK2-R462Xintheforebrainofmicecanbe
monitored by changes in the behavior. (A) Grouping of rAAV-Syn-GFP P0
injected mice. Fluorescence overview images of one brain hemisphere from
eight mice at P210+2 (mouse numbers are indicated). Scale bar, 500 mm.
On the right, a ﬂuorescence overview image of a coronal brain section from
mouse number1 (#1) is depicted. Scale bar, 500 mm. (B) Immunoblot analysis
of hippocampal extracts prepared from mice shown in (A). (C) Grouping of
rAAV-Syn-Venus-SHANK2-R462X P0 injected mice. Diagram of rAAV-Syn-
Venus-SHANK2-R462Xvector.Overviewimageofonebrainhemispherefrom
eight injected mice at P210+2. Exposure conditions were kept constant com-
pared with the middle row in (A). A color-adjusted overview image of the
coronalbrainsectionfrommousenumber2(#2)isgivenontheright.(D)Immu-
noblot analysis of hippocampal extracts from the mice described in the middle
rows. The anti-SHANK2 and anti-GFP antibodies identiﬁed relative levels of
SHANK2-R462X expression (relative quantiﬁcation from left to right 2.1,
2.2, 3.4, 3.3, 3.7, 1.9, 3.0, 1.9). Mice were divided into low-expression (L)
andhigh-expression(H)groups.Immunosignalsobtainedwithanti-GluA1,anti-
GluA2werecomparablebetweenallanimals.(E)Anti-Phospho-Ser831-GluA1
and anti-Phospho-Ser845-GluA1 antibody showed no difference of phosphory-
lated GluA1 between low-expression and high-expression animals.
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patients with ASD: a de novo stop mutation and a missense
and duplication mutant that were inherited from apparently
normal mothers. Transmitted variants with variable penetrance
are commonly termed ‘unclassiﬁed variants’ since the genetic
background is critical for their phenotypic expression. To
address whether functional differences exist between muta-
tions with high and low penetrance, we carried out overexpres-
sion and rescue experiments in primary hippocampal neurons.
We can demonstrate that all three analyzed mutants are
loss-of-function mutations, yet of variable phenotypic range
and intensity with respect to alterations in spine volume, den-
dritic arbor complexity and postsynaptic clustering. Whereas
the duplication variant presented the mildest, the R462X
variant presented the most severe phenotype.
What may be the underlying molecular mechanisms of the
different phenotypes? The duplication of L1008_P1009dup
resides in the prolin-rich region, in the vicinity of the
Homer-binding motif. This might translate into only a subtle
structural change of minor interference with SHANK2 func-
tions. The T1127M exchange in the highly conserved
Dynamin-2-binding site might disturb the interaction of
SHANK2 with Dynamin 2. This could result in altered glutam-
ate receptor trafﬁcking and interfere with other processes of
postsynaptic membrane turnover (16). SHANK2 is connected
to the actin cytoskeleton via Cortactin and to metabotropic
glutamate receptors via Homer. The truncated R462X
mutant lost the binding motifs for Homer, Cortactin and
Dynamin 2 as well as the C-terminal SAM domain, which is
essential for the correct localization of the protein (17).
R462X is mislocalized and therefore likely lost the connection
to metabotropic glutamate receptors and to the actin cytoskel-
eton, suggesting that multiple functions of the protein are dis-
rupted. In contrast, the T1127M and duplication variants seem
to disturb only one functional aspect of the SHANK2 protein
and therefore have a more subtle effect on neuronal morph-
ology. Thus, different variants have different limitations: the
L1008_1009dup mutation can rescue the Shank2 knock-down,
yet in the overexpression experiment it is not able to increase
spine volume as much as SHANK2 WT protein. The T1127M
mutation is able to rescue the dendritic arbor phenotype but
not the spine volume and also cannot increase spine volume
when overexpressed. The functional effect of these two var-
iants suggests that they represent a risk factor for ASD
rather than being sufﬁcient to cause the full-blown ASD
phenotype. These data strongly suggest that more than one
variant (of different genes) will need to be affected in these
cases to reach the threshold for a fully penetrant phenotype.
To study the effect of the most dysfunctional SHANK2
variant R462X in vivo, overexpression experiments were
carried out using a virus-based delivery system in the CNS
of mice. We could show that the loss of function of R462X
correlates with dominant negative effects, as demonstrated
by a reduced average mEPSC amplitude in principal neurons
expressing endogenous Shank2 protein. Since the very same
neurons showed comparable inhibitory drive and the mEPSC
kinetics were similar to those from uninfected cells, a postsy-
naptic reduction in the density of AMPA receptors might be
the primary reason for the reduced amplitude of spontaneous
excitatory activity into these neurons. This view is supported
by our ﬁnding that SHANK2-R462X expression leads to a
reduction of AMPA receptors in spine heads. Furthermore,
the analysis of the total number of AMPA receptor subunit
levels and AMPA receptor clusters in the stratum radiatum
of the hippocampus showed that the reduced AMPA receptor
currents are not due to a reduced AMPA receptor expression
but may be mediated instead by alterations in the distribution
of synaptic and extrasynaptic AMPA receptors in those
neurons expressing SHANK2-R462X. The direct effect of
SHANK2-R462X on AMPA receptor distribution and
AMPA receptor currents is supported.
We speculate that the distribution of synaptic AMPA recep-
tors is altered only in those neurons expressing
SHANK2-R462X and therefore cannot be biochemically
detected by a cell population analysis of neurons on western
blot. The direct effect of SHANK2-R462X on AMPA receptor
currents is supported by the ﬁnding that the reduction of
mEPSCs could already be observed in principal neurons 2
weeks after SHANK2-R462X expression in adult mice,
excluding that only deﬁciencies during maturation or activity-
dependent modulation of the neuronal networks result in a
phenotype.
The dominance of SHANK2-R462X also became apparent
in the behavioral performance of mice overexpressing this
variant postnatally, leading to impaired cognitive functions.
The behavior analysis was used as a read-out for the physio-
logical effect of the variant and should not be considered a
model for ASD in the mouse. Impairments were detected in
novel object exploration and in the puzzle box, where mice
showed reduced interest to novel objects and failed to solve
more complex executive functions in a dose-dependent way.
It has to be considered, however, that the viral mediated
gene transfer leads to a strong mosaic expression of
SHANK2-R462X. For this reason, we cannot differentiate
whether the number of neurons expressing SHANK2-R462X
or its expression level is crucial. Mouse models with well-
deﬁned SHANK2-R462X expression or SHANK2 haploinsuf-
ﬁciency are required to reveal whether the observed behavioral
phenotypes in our viral transduced SHANK2-R462X mouse
models can be recognized as an experimental mirror image
for autistic disorder in humans.
Haploinsufﬁciency of SHANK2 might be one parameter
underlying ASD. By RNA interference, we could show that
knock-down of Shank2 leads to thin immature and ﬁlopodia-
like dendritic spines, with a reduced number of synaptic con-
tacts in primary hippocampal neurons of Rattus norvegicus,
which is consistent with the ﬁndings reported by Grabrucker
et al.( 18). Spine morphology is known to be intimately
linked to synapse function: smaller spines are usually corre-
lated with smaller synapses and reduced synaptic transmission
(19). The striking increase in dendritic arbor structures in
neurons lacking Shank2 has not been described before and
likely reﬂects a loss of strong synaptic contacts, since dendritic
arbor development and stabilization are tied to the strength of
synaptic inputs received by the developing neuron (20). Loss
of Shank2 might therefore cause defects in synaptic signal
processing or result in a misbalance between excitatory and
inhibitory signals in the brain of individuals with ASD and ID.
Our data further indicate that the reduction of Shank2 alone
is sufﬁcient to elicit a spine phenotype, suggesting that there is
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context of spine morphology. Shank2 is the ﬁrst family
member to appear at PSDs, whereas the recruitment of
Shank3 and Shank1 occurs later in development (18).
Shank2 is therefore likely involved in the initial steps of
PSD assembly, and may have a function in the signal-
dependent recruitment and cross-linking of the other Shank
paralogs. Although SHANK3 mutations have been shown to
cause ASD, ID and schizophrenia (21,22), Shank1 has not
been associated with any disease phenotype yet. Mice
lacking Shank3 show an autistic-like phenotype with an
altered neuronal connectivity (23).
Individuals with ASD often present ID. In postmortem
studies of individuals with ASD, effects on the dendritic and
spine morphology have been described but the pattern of
neuropathology is very heterogenous (24). Comparing the
morphological alterations seen in cultured hippocampal
neurons by Shank2 knock-down with the literature, an
almost identical effect on spine morphology was noted to
the RNAi-mediated knock-down of the PAK3 and
ARHGEF6 ID genes (25). In addition, postmortem brain ma-
terial of individuals with Fragile X, the most common inher-
ited cause of ID, displays remarkably similar features with
altered dendritic spine morphology and a large proportion of
abnormally long, thin, ﬁlopodia-like, immature dendritic
spines (26). Yet, it is not clear if the excess of ﬁlopodia-like
spines in Fragile X patients represents functional synapses or
immature synaptic precursors.
Proteins like FMRP and SHANK are central regulators of
synaptic organization and function and genetic defects of
these genes have effects on spine morphology and synaptic
function. This may result in an imbalance of excitatory and
inhibitory synaptic signaling and thereby disturb the homeo-
stasis of the complex neuronal networks (5), demonstrating
how defects in different genes can result in comparable clinic-
al outcomes. Re-establishing the balance between excitatory
and inhibitory signaling in the brain might therefore be a
suitable therapeutic approach. GABAA receptor agonists and
Figure 6. Behavioral analyses of adult mice expressing SHANK2_R462X (shown in Fig. 5). (A) Both SHANK2-R462X-L and -H cohorts showed unaltered
activity in the open ﬁeld when compared with GFP-expressing controls. (B) In the novel object test, group comparisons by two-way ANOVA exhibited differ-
ences in the goal region depending on the presence of the novel object (F(1,26) ¼ 7.951; P , 0.01). Post hoc tests demonstrated that only GFP-expressing controls
exhibited signiﬁcantly higher object approaches after introducing the object into the center of the arena. (C) No difference of anxiety-related behavior (time spent
in lit compartment) was found in the light–dark box test. (D) In the puzzle box test, the transition from the light to the dark compartment through a gate (trials 1
and 11) or a tunnel (trials 2–9) requires altering strategies as indicated at the bottom. The tunnel is open in trials 2–4, ﬁlled with sawdust in trials 5–7 and
covered by a plug in trials 8–10, whereas trial 11 corresponds to trial 1. Repeated-measures ANOVA exhibited a signiﬁcant genotype effect (F(2,130) ¼
4,298; P , 0.05), whereas Bonferroni-corrected analyses showed a signiﬁcant impairment of SHANK2-R462X-high expressing mice compared with both
other groups during trial 10. ∗P ≤ 0.01.
Human Molecular Genetics, 2012, Vol. 21, No. 2 353mGluR5 antagonists are presently being tested in clinical
studies in both individuals with autism and Fragile X
syndrome (27).
MATERIALS AND METHODS
Ethics statement
All experimental procedures were performed according to the
animal welfare guidelines of the Max Planck Society (Charles
River). Animal experiments were performed under the license
at the Regierungspra ¨sidium Karlsruhe 35-915.81/G-71/10,
35-915.81/G-56/02 and 35-915.81/G-49/09.
Plasmid constructs
Cloning of SHANK2, with the partial coding sequence from
KIAA1022fg00613 clone (accession number AB028945,
Kazusa DNA Research Institute, Japan), into the pENTR2B
vector (Invitrogen) was via SalI and EcoRV restriction sites,
and SalI and PshAI in the KIAA construct. The N-terminal
part of SHANK2 was PCR-ampliﬁed from human brain
cDNA, introducing a SalI restriction site at the 5′end. The
PCR product was inserted into pENTR2B-KIAA1022 using
SalIand SacI, resulting in pENTR2B-SHANK2-WT. Mutagen-
esis was performed using the QuikChange Lightning Site-
directed Mutagenesis Kit (Stratagene) on 70 ng of SHANK2
WT plasmid to generate the L1008_P1009dup, T1127M and
R462X mutants. Each clone was puriﬁed with the Pure Yield
Plasmid Midiprep System (Promega) and sequenced to rule
out additional mutations. For ﬂuorescence image analysis, the
SHANK2 WT and mutant constructs were transferred to
pcDNA3.1-mCherry-DEST vector using the Gateway recom-
binant technology (Invitrogen). The cloning of Shank2 from
Rattus norvegicus was performed using cDNA from the rat
brain P18 prefrontal cortex as a template for PCR, with the
primers amplifying the smallest neuronal isoform of rat-
Shank2, introducing an N-terminal BamHI and a C-terminal
NotI restriction site. The PCR fragment was cloned into
pENTR3C (Invitrogen) and then transferred into
pcDNA3.1-FLAG-DEST vector (generated in our laboratory).
The pSUPER RNAi expression system was used for siRNA-
mediated knock-down of SHANK2. Two independent
pSUPER constructs were generated with BglI and HindIII
restriction sites (see primer sequences). The co-shRNA is
described elsewhere (28). The pGW1-HA-Shank1 and Shank3
expression constructs were used as described (29). For the
AAV plasmids, the SHANK2-WT and SHANK2-R462X
sequences were sub-cloned into the pAAV-Syn-Venus vector
(30), generating pAAV-Syn-Venus-SHANK2-WT and
pAAV-Syn-Venus-SHANK2-R462X plasmids.
Cell culture and transfection
Dissociated primary hippocampal neurons from embryonic day
18 (E18) Sprague–Dawley rats (Charles River Laboratories,
Sulzfeld, Germany) were prepared and cultured as described
elsewhere (28). Neurons were transfected after 10 days in
culture (10 DIV) with Lipofectamine 2000 (Invitrogen), using
a total of 1 mg of DNA (500 ng SHANK2 construct or mutant,
100 ng of GFP-plasmid, 400 ng of pcDNA3-vector) for each
well of a 24-well plate. HEK293 cells were maintained in
DMEM (GIBCO) plus 10% FCS, 1 mM glutamine, 100 U/ml
penicillin and streptomycin. Transfections of the different con-
structs were performed with Lipofectamine 2000. For shRNA
experiments, pSUPER plasmids were used either at 1.5 mg/ml
(HEK293 cells, together with 0.5 mg/ml of the Shank con-
structs) or at 5 ng/ml (primary neurons). Rescue experiments
in primary hippocampal neurons were performed with 5 ng/ml
pSUPER-shRNA #2, 125 ng/ml of SHANK2 WT or mutant
constructs and 50 ng/ml of GFP plasmid DNA. For the GFP
control, we added 125 ng/ml of pcDNA3.1-mCherry-DEST
vector and 50 ng/ml of GFP plasmid DNA. pcDNA3.1 vector
was calculated to reach a ﬁnal concentration of 500 ng/ml of
total DNA for each reaction.
Virus infection
Recombinant AAVs were generated as described (30), and
puriﬁed by afﬁnity chromatography (31). Virus titers were
determined in hippocampal primary cultures (1.0 × 10
7–10
8
particles/ml). For adult infections, viruses were delivered
into the brain of deeply anesthetized (ketamine/xylazine
mix) 6-week-old C57BL/6N mice (Charles River) by stereo-
tactic injections (30). Stereotactic coordinates relative to the
bragma were: anteroposterior (AP) 2.1 mm, lateral
+1.6 mm, depth 0.3–1.6 mm for hippocampal and cortical
injections (one puriﬁed virus/injection). For P0 injection,
mice from two litters of C57BL6/N mice (Charles River)
were randomly injected with either rAAV-Syn-GFP or
rAAV-Syn-Venus-SHANK2-R462X virus at postnatal day
0. The rAAV viruses were injected in both hemispheres tar-
geted to the hippocampus. Each mouse received two injections
on each hemisphere: AP 1.0 mm, lateral +1.0 mm, depth
1.6 mm; AP 2.0 mm, lateral +1.0 mm, depth 1.5 mm; 1
(microlitres puriﬁed virus/injection site).
After injection, the pups were put back to the home cage
with their mothers. The identiﬁcation of the injected virus in
the animal was done postmortem after the behavior analysis
by immunoblotting.
Brain sections
Mice were anesthetized with isoﬂuran and either decapitated
directly or perfused intracardially with warm 1× PBS
(137 mM NaCl, 2.7 mM KCl, 4.3 mM Na2HPO4/2H2O,
1.4 mM KH2PO4) and 4% paraformaldehyde (PFA) in PBS
prior to decapitation. Brains were removed and ﬁxed in
ice-cold 4% PFA for 2 h, embedded in 2.5% agarose/PBS
and sliced on a vibratome into 70–100 mm sections.
Immunocytochemistry
Hippocampal primary neurons were ﬁxed on 18 DIV in 4%
PFA for 15 min, permeabilized with PBS plus 0.2% Triton
X-100 and blocked in PBS containing 10% normal goat
serum. We used a rabbit polyclonal anti-synapsin-1 antibody
(1:500, Chemicon), a mouse anti-Shank2 antibody (1:500;
NeuroMab, Antibodies, Inc.) or a mouse anti-PSD95 antibody
(1:500; NeuroMab, Antibodies, Inc.) together with Alexa
354 Human Molecular Genetics, 2012, Vol. 21, No. 2Fluor 647 goat anti-rabbit (1:1000; Invitrogen) or Alexa Fluor
568 rabbit anti-mouse (1:1000, Invitrogen). Virus-injected
mice were ﬁxed with 4% PFA/PBS, and 70 mm sections
were obtained from the brain. Staining of brain sections was
done with rabbit anti-GFP antibody (1:5000, Abcam) and
FITC-coupled anti-rabbit secondary antibody (1:200, Jackson
ImmunoResearch). For the GluA1 cluster staining, the brain
sections were treated at 378C for 10 min with 0.3 mg/ml
Pepsin (DAKO Carpinteria) in 0.2 N HCl and washed brieﬂy
in PBS before immunostaining. The sections were incubated
with rabbit anti-GluA1 (1:1000, Abcam) and followed with
Cy3-coupled anti-rabbit secondary antibody (1:500, Jackson
ImmunoResearch). The Golgi staining was performed with
the commercial FD Rapid GolgiStain
TM Kit (FD Neuro-
Technologies).
Image analysis
To determine the effect on spine volume in primary hippocam-
pal neurons, the SHANK2 constructs were co-transfected with
GFP and processed for confocal microscopy at 18 DIV. High-
resolution z-stack images of GFP-positive neurons were taken
with the 63× objective of the confocal laser scanning micro-
scope (Zeiss). Neurons displaying pyramidal morphology
were chosen randomly and spine volumes were subsequently
analyzed with the ImageJ software. Signal intensity levels of
each construct were similar, excluding the possibility of
effects of transfection efﬁciencies. The clustering properties
of SHANK2 constructs were quantiﬁed by calculating the syn-
aptic clustering ratio (SCR), the ratio of the average pixel in-
tensity in dendrites versus spine heads. Transfected neurons
were randomly chosen for each construct from two independ-
ent transfections (12 cells per construct). The average pixel in-
tensity was measured in dendrites (excluding the spine heads)
and in the spine heads by tracing their individual perimeters.
The size of SHANK2 construct clusters and the endogeneous
Shank2 clusters in dendritic spines as well as the synaptic
density measures were determined with the ‘analyze particle’
function of the ImageJ 1.41f software, using threshold images.
Particles ,0.1 mm
2 were excluded from the analysis. For the
brain sections, evaluation of the immunostaining and Golgi
staining was done with confocal microscopy (SP2, Leica)
using either 5× for overview or 63× for high-magniﬁcation
images. Two mice from each genotype were used for the
GluA1 cluster staining. The laser power of confocal micros-
copy was kept the same during all recordings. In the stratum
radiatum region of the hippocampus, 4 stacks containing 40
images each with an area of 29.7 × 29.7 mm
2 and an interval
of 81 nm were taken for the analysis. All stacks were ﬁrst
restored with the deconvolution software HuygensPro (SVI
Systems) applying CMLE with 300 iterations, 0.0001%
quality threshold and a theoretical point spread function.
Deconvoluted images were then imported to ImageJ for par-
ticle counting analysis using a ﬁxed threshold algorithm.
Western blot analysis
Infected hippocampal tissue of mouse brains was collected and
homogenized in ice-cold buffer (25 mM HEPES, pH 7.4) con-
taining a protease inhibitor cocktail (Complete, Roche,
Pharma AG). After 5 min of 2000 r.p.m. low centrifugation,
the supernatnant containing total proteins was collected. For
membrane proteins, they were obtained by 13 000 r.p.m. high
centrifugation of the pellets. Of total and membrane proteins,
5 mg was separated by SDS–PAGE (10% separating and 4%
stacking gels) and transferred to nitrocellulose membranes.
Western blots were probed with monoclonal mouse anti-GFP
(1:10000, Abcam), polyclonal rabbit anti-GluA1 (1:5000,
Abcam), monoclonal mouse anti-GluA2, monoclonal
mouse anti-SHANK2 (1:2000), monoclonal rabbit anti-
pospho-Ser831-GluA1 (1:8000, Millipore), monoclonal rabbit
anti-phospho-Ser845-GluA1 (1:2000, Millipore), polyclonal
rabbit anti-P38 (1:2000, Abcam) and monoclonal mouse anti-
GAPDH(1:5000,Abcam).Fluorescentcoupledsecondaryanti-
bodies anti-rabbit IgG (IRDye800DX, 1:10 000, Rockland) and
anti-mouse IgG (IRDye700DX, 1:5000, Rockland) were used.
Fluorescence was detected by the ﬂuorescence imaging
scanner (Starion/FLA9000, GE-Healthcare). Quantiﬁcation of
western blots was done using Multi-Gauge (Fuji-Film) and
Image J (NIH).
Electrophysiology
The brain of mice was dissected out and combined EC-dorsal
hippocampus slices (350 mm) were cut in the horizontal plane
(HM 650 V, Microm International, Walldorf, Germany) in a
dissection buffer (48C) containing (in mM): 212.7 sucrose,
5 KCl, 1.25 NaH2PO4, 10 MgCl2, 0.5 CaCl2, 26 NaHCO3,
10 dextrose, saturated with 95% O2/5% CO2 (pH 7.4). Individ-
ual slices were gently transferred to normal artiﬁcial cerebro-
spinal ﬂuid (ACSF) for at least 1 h prior to recording. Normal
ACSF was similar to the dissection buffer except that sucrose
was replaced by 119 mM NaCl, MgCl2 lowered to 1 mM and
CaCl2 raised to 2 mM. Visualized whole-cell recordings
(IR-DIC, Axioskop 2 FS mot, Zeiss International, Germany)
were made from EC layer 2/3 (≥ 35% depth from the pia),
and from hippocampal CA1 pyramidal cells. Cortical pyram-
idal cells were identiﬁed by their pyramidal shaped, prominent
apical dendrites and regular spiking pattern in response to
depolarizing current (0.1–0.5 nA, 1 s). A subset of 20
pyramidal-like cells was ﬁlled with 0.1% Lucifer yellow
and we found that 95% were spine-containing pyramidal
cells, validating the selection criteria. Borosillicate glass
recording pipettes (4–6 MV) were ﬁlled with intracellular
solution containing (in mM): 130 (Cs)gluconate, 5.5 KCl,
1 EGTA (pH 8), 10 HEPES, 4 (Mg)ATP, 0.5 (Na3)GTP,
10 (Na2)phosphocreatine and 5 QX-314 (lidocaine N-ethyl
bromide) (pH 7.25, 280–290 mOsm), and a liquid junction
potential of 16.3 mV was compensated (308C). Only cells
with holding currents ≤100 pA, series resistance ≤20 MV
and input resistance ≥150 MV were studied. Cells were dis-
carded if any of these control parameters, monitored with a
100 ms voltage pulse of 210 mV, changed ≥20% between
two ﬂanking epochs sampled at the beginning and end of the
recordings. Data were ﬁltered at 2 kHz and digitized at
5 kHz using an EPC-10 ampliﬁer controlled by Patchmaster
(HekaElektronik, Lambrecht, Germany). We quantiﬁed the
net excitatory and inhibitory postsynaptic drive from the
same recorded cells. Spontaneous miniature excitatory and in-
hibitory currents (mPSCs) were recorded in the presence of
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phosphonovaleric acid (50 mMD ,L-APV, Biotrend) and CGP
55845 (2 mM, Biotrend), all diluted in the ASCF at 2 ml/min,
30+18C. To isolate AMPAR-mediated miniature currents
(hereafter referred to as mEPSCs), neurons were held at
Vh¼ 270 mV [EAMPA¼ 6.21+0.84 mV, n ¼ 11, in
(–)-bicucullinemethiodide; 20 mM, Sigma Aldrich], whereas
for GABAA-mediated inhibitory currents (hereafter referred
to as mIPSCs), neurons were held at Vh¼ 0m V[ EGABAA ¼
267.62+3.10 mV, n ¼ 15, estimated in the presence of
6-nitro-7-sulfamoyl-benzo(f)quinoxaline-2,3-dione, 10 mM,
NBQX, Biotrend]. Spontaneous currents were detected and
analyzed using the Mini Analysis Program (Synaptosoft,
Inc.) with a threshold set at three and ﬁve times the RMS of
membrane current noise, for mEPSCs and mIPSCs, respective-
ly. Cells showing a negative correlation between mPSC amp-
litude and rise time were excluded from this analysis (i.e.
dendritic ﬁltering present). The ﬁrst 300 events/cell with rise
time ≤3 ms for mEPSCs (≤5 ms for mIPSCs) were used to
estimate the cell’s mPSC amplitude and frequency distribu-
tions. At least two cells per animal were recorded and
average amplitude and frequency (per animal) were compared
across interleaved experimental conditions.
Mouse behavior analysis
Mice were housed four per cage in an animal room with con-
stant temperature (22+18C) and adapted to a new 12 h light/
dark cycle with free access to food and water. Experiments
were performed between 10 a.m. and 5 p.m. during the light
phase. One week prior to starting the tests, mice were single-
housed and handled extensively (15 min per mouse per day) to
reduce their anxiety and get acquainted with the testing
environment (32).
Statistical analysis
Data are presented as mean+SD unless otherwise stated.
Testing for normal distribution was made by the Kolmo-
gorov–Smirnov or the Shapiro–Wilk test. Concerning the
experiments in primary hippocampal neurons, the comparisons
of mean differences between groups were made using the
two-way ANOVA test including the different conditions
and controlling for the different replicates followed by a
Scheffe ´ post hoc test with signiﬁcance levels for both set at P
, 0.05. ANOVA P-values are shown for the different condi-
tions. mPSC amplitudes were statistically compared using an
unbalanced one-way ANOVA test and their cumulative distri-
butionswithaKolmogorov–Smirnovtest.Averagefrequencies
were compared by using an ANOVA test followed by Fisher’s
protected least signiﬁcant difference (PLSD) post hoc test.
mPSC kinetics were compared using an unpaired Student’s
t-test followed by a Scheffe ´’ post hoc test. Signiﬁcance levels
were set at P , 0.05. Group plots are presented as average+
SEM. Tests were performed with programs written in
MATLAB 7.8 (R2009a; MathWorks, Inc.) or SPSS 16.0 soft-
ware for Windows. For the behavior tests, one-way ANOVA
was performed for the open-ﬁeld activity tests; two-way
ANOVA followed by post hoc Bonferroni test was done for
the open-ﬁeld novel object exploration test; light/dark box test
was compared with one-way ANOVA and both two-way
ANOVA and repeated measurement ANOVA were applied
for the puzzle box test, showing similar results. Mann–
Whitney tests (nonparametric test) were performed for both
GluA1 cluster number and size counting analysis.
SUPPLEMENTARY MATERIAL
Supplementary Material is available at HMG online.
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